Zurich, May 25, 2026, 16:03 (CEST)
Molecular Partners AG goes into a closed-market Monday with momentum but no fresh trading: its SIX-listed shares last closed at CHF 3.15 on Friday, up 9.38%, after touching an intraday high of CHF 3.19. The move left the stock still below its 52-week high of CHF 3.96 and above the CHF 2.66 low set on May 13.
The pause matters. SIX Swiss Exchange is shut on May 25 for Whit Monday, while U.S. markets are closed for Memorial Day, leaving Molecular Partners’ Zurich line and Nasdaq ADS without a live Monday price. The company’s own stock page listed the Nasdaq line at $4.18 after Friday trading.
The stock’s next test is less about the holiday and more about data timing. Molecular Partners said it will present on MP0712, its lead Radio-DARPin candidate, at the Antibody & Engineering Therapeutics meeting in Basel on May 29, under a session title that includes “first in human insights.” A Radio-DARPin is an engineered protein designed to carry a radioactive payload to cancer cells. Molecular Partners
Molecular Partners has been trying to shift attention from a long spell of losses to its oncology pipeline. A Securities and Exchange Commission filing showed no revenue in the first quarter, R&D costs of CHF 9.45 million and a net loss attributable to shareholders of CHF 13.14 million, narrower than CHF 16.77 million a year earlier.
The company said this month it had CHF 79 million in cash, cash equivalents and short-term deposits at the end of March. Management said that cash runway — the period it expects to fund operations without new capital — should last into late 2027.
Chief Executive Patrick Amstutz said MP0712 was advancing with “initial data anticipated this year” and pointed to a “strong financial position” supporting the pipeline. The company said the U.S. Phase 1/2a study, an early trial stage that tests safety and dose before broader efficacy work, had four clinical sites open and nine expected by year-end. Molecular Partners
MP0712 targets DLL3, a tumor-linked protein seen in small cell lung cancer and other neuroendocrine cancers. It carries lead-212, a radioactive isotope, and is being co-developed with Orano Med; the trial aims to assess safety and determine a recommended Phase 2 dose.
There is another clinical thread. Molecular Partners said Phase 1 data for MP0317, a tumor-localized CD40 agonist, were published in Nature Cancer, while an investigator-led Phase 2 cholangiocarcinoma study was open with eight sites activated and a planned 75 patients. Coordinating investigator Philippe Cassier of Centre Léon Bérard said the data showed an ability to “turn cold tumors hot,” meaning to make tumors more visible to immune attack. Molecular Partners
The competitive backdrop is not quiet. Novartis, a much larger Swiss peer in radioligand therapy, said in February it would build a Texas facility, its fifth U.S. site, to produce targeted cancer treatments including Pluvicto and Lutathera. That keeps pressure on smaller developers such as Molecular Partners to show their platforms can offer something different, not just another radioactive payload.
But the risks are plain. Friday’s jump may fade when trading reopens, especially in a small-cap biotech where volume can thin around holidays, and the company is still early in clinical development. Molecular Partners also cautioned that interim data can differ from later topline results and that clinical-development expectations carry uncertainty.
For the week ahead, traders will watch whether MOLN can hold Friday’s close and whether the Basel presentation adds detail beyond what the company has already flagged. The larger question remains the same: whether 2026 clinical readouts can turn a short price bounce into a more durable re-rating.
